FORM PTO-1449/A and B (Modified)	APPLICATION NO.: unassigned	ATTY. DOCKET NO.:N00260.70058.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Herewith	CONFIRMATION NO.: unassigned
	APPLICANT: Shashoua et al.	
Sheet 1 of 7	GROUP ART UNIT: unassigned	EXAMINER: unassigned

U.S. Patent Documents

Exam Init	Ref Des	Document No.		Date	Name	FILING DATE If Appropriate
	*	2001/0006892	A1	07-05-2001	Myhren et al.	
	*	6,291,690	B1	09-18-2001	Mayhew et al.	
	*	6,281,376		08-28-2001	Whittaker et al.	
	*	6,258,836			Shashoua	
	*	6,252,060		06-26-2001	Hostetler	
	*	6,225,460		05-01-2001	Bischofberger et al.	
	*	6,166,089		12-26-2000	Kozak	
	*	6,136,796		06-20-2000	Kozak	
	*	6,077,837		06-20-2000	Kozak	
	*	6,069,249		05-30-2000	Arimilli et al.	
	*	6,043,230		03-28-2000	Arimilli et al.	
	*	5,977,174	B1	11-02-1999	Bradley et al.	
	*	5,994,392		11-30-1999	Shashoua	
	*	5,985,854		10-24-2000	Kozak	
	*	5,977,089		11-02-1999	Arimilli et al.	
	*	5,977,061		11-02-1999	Holy et al.	
	*	5,922,695		07-13-1999	Arimilli et al.	
	*	5,716,614		02-10-1998	Katz et al.	
	*	5,459,256		10-17-1995	Marquez et al.	
	*	5,420,276		05-30-1995	Norbeck	
	*	5,223,263		06-29-1993	Hostetler et al.	
	*	5,194,654		03-16-1993	Hostetler et al.	
	*	5,059,699		10-22-1991	Kingston et al.	
	*	5,278,324		01-11-1994	Kingston et al.	
	*	5,534,499		07-09-1996	Ansell	
	*	6,291,690		09-18-2001	Mayhew et al.	
	*	5,925,669		07/1999	Katz, et al.	
	*	5,919,815		07/06/99	Bradley, et al.	
	*	5,814,456		09/29/98	O'Rand, et al.	
	*	5,795,909		08/18/98	Shashoua, et al.	
	*	5,750,572		05/12/98	Bruzzese	
	*	5,654,290		08/05/97	Bayon, et al.	
	*	5,604,216		02/18/97	Horrobin	
	*	5,597,719		01/28/97	Freed, et al.	
	*	5,580,899		12/03/96	Mayhew, et al.	
	*	5,580,556		12/03/96	Horribin	
	*	5,516,800		05/14/96	Horrobin	
	*	5,504,102		04/02/96	Agharkar, et al.	

	*	5,484,876		2/94	Shashoua, et al.	
	*	5,484,809		01/16/96	Hostetler, et al.	
	*	5,496,714		03/05/96	Comb, et al.	
	*	5,494,999		02/27/96	Hale, et al.	
	*	5,476,954		12/19/95	Bourzat, et al.	
	*	5,473,055		12/05/95	Mongelli, et al.	
	*	5,468,754		11/21/95	Hausheer, et al.	
	*	5,453,521		09/26/95	Gaullier, et al.	
	*	5,453,520		09/26/95	Bombardelli, et al.	
	*	5,447,936		09/05/95	Hausheer, et al.	
	*	5,466,841		11/14/95	Horrobin, et al.	
	*	5,411,947		05/02/95	Hostetler, et al.	
	*	5,362,831		11/08/94	Mongelli, et al.	
	*	5,356,928		10/18/94	Murray et al.	
	*	5,352,596		10/04/94	Cheung, et al.	
	*	5,336,684		08/09/94	Murray, et al.	
	*	5,314,991		05/24/94	Oka, et al.	
	*	5,308,832		05/03/94	Garleb, et al.	
	*	5,276,020		1/94	Horribin, et al.	
	*	5,250,722		10/05/93	Bombardelli, et al.	
	*	5,246,726		09/21/93	Horrobin, et al.	
	*	5,223,263		06/29/93	Hostetler, et al.	
	*	5,216,142		06/01/93	Horribin, et al.	
	*	5,216,023		06/01/93	Literati-Nagy, et al.	
	*	5,214,062		05/25/93	Mark, et al.	
	*	5,194,654		03/16/93	Hostetler, et al.	
	*	5,169,764		12/92	Shooter, et al.	
	*	5,141,958		08/25/92	Crozier-Willi, et al.	
	*	5,120,760		06/09/92	Horrobin	
	*	5,116,624		05/26/92	Horrobin, et al.	
	*	5,112,863		05/12/92	Hashimoto, et al.	
	*	5,112,596		5/92	Malfroy-Camine	
	*	5,068,224		11/91	Fryklund, et al.	
	*	4,968,672		11/06/90	Jacobson, et al.	
	*	4,943,579		07/24/90	Vishnuvajjala, et al.	
	*	4,857,653		08/15/89	Colin, et al.	
	*	4,814,470		03/21/98	Colin, et al.	
	*	4,788,062		11/28/88	Fisher, et al.	
	*	4,729,989		03/08/88	Alexander	
	*	4,704,393		11/03/87	Wakabayashi, et al.	
	*	4,692,441		09/08/87	Alexander, et al.	
	*	4,636,494		01/13/87	Growden, et al.	
	*	4,407,744		10/83	D.M. Young	
	*	4,287,184		9/81	D.M. Young	
	*	4,185,095		1/80	D.M. Young	
	*	4,088,646		05/09/78	Ishida, et al.	
	*	6,080,877		06/27/00	Swindell, et al.	
	*	6,153,653	B1	11-28-2000	Shashoua	
	*	6,197,764	B1	03-06-2001	Bradley et al.	

	*	6,225,444	B1	05-01-2001	Shashoua	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Office/Country	Publication Date	Name of Patentee or Applicant of Cited Document (not necessary)	Class	Sub Class	Translation Yes	Translation No
	*	0 350 287	10/90	EPO				
	*	0 693 498 A1	1/96	EPO				
	*	0 615 762 A1	9/94	EPO				
	*	0 030 009 A1	06/81	EPO				
	*	8163991A	06/25/96	Japan			X	
	*	DE 2602175	07/29/76	Germany				
	*	2 698 269 A	08/05/97	France				
	*	JP 9025231A	01/28/97	Japan			X	
	*	JP 8027010A	01/30/96	Japan			X	
	*	JP 76-9469	01/22/75	Japan				
	*	JP 6016548A	01/25/94	Japan			X	
	*	75-427/1983	4/83	Japan (English Abstract)			X	
	*	59025327A	02/09/84	Japan			X	
	*	JP 1153629A	06/15/89	Japan			X	
	*	1287022A	11/17/89	Japan			X	
	*	JP 1203331A	08/16/89	Japan			X	
	*	JP 9030963	2/97	Japan			X	
	*	JP 815133	6/96	Japan			X	
	*	JP 59-204175	11/84	Japan (English Abstract)				
	*	ZA 9603433A	10/30/96	South Africa				
	*	WO 98/32718	07/30/98	NORSK HYDRO				
	*	WO 98/21223	05/22/98	PCT				
	*	WO 97/44336	11/27/97	PCT (7018 WO)				
	*	WO 97/44063	11/27/97	PCT (7020 WO)				
	*	WO 97/44026	11/27/97	PCT (7019 WO)				
	*	WO 96/27380	09/96	PCT				
	*	WO 96/12696	05/96	PCT				
	*	WO 96/01259	1/1996	PCT				
	*	WO 95/33736	12/1995	PCT				
	*	WO 95/13271	5/1995	PCT				
	*	WO 95/13270	5/1995	PCT				
	*	WO 95/01969	1/1995	PCT				
	*	WO 94/24107	10/1994	PCT				
	*	WO 94/13654	6/1994	PCT				
	*	WO 94/12530	6/1994	PCT				
	*	WO 94/11547	5/1994	PCT				
	*	WO 94/07880	4/1994	PCT				
	*	DE 422 4737	2/94	Germany				
	*	WO 94/22887	10/1994	PCT				

	*	WO 94/12530	6/1994	PCT				
	*	WO 93/00919	01/21/93	PCT				
	*	WO 92/20362	11/26/92	PCT (7007 WO)				
	*	WO 92/16554	10/92	PCT				
	*	WO 99/52887	10/21/99	PCT				
	*	WO 93/11668	06/24/93	PCT				
	*	WO 90/00555	01/25/90	PCT				
	*	WO 89/02733	04/06/89	PCT				

Other Art

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.		
DJ	*	CHEN, et al. "Taxol Structure-Activity Relationships: Synthesis and Biological Evaluation of Taxol Analogs Modified at C-7," *Bioorganic & Medicinal Chemistry Letters*, Vol. 4, No. 18, pp. 2223-2228, 1994.		
	*	DE GROOT, et al., "Synthesis and Biological Evaluation of 2'-Carbamate-Linked and 2'-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin," *J. Med. Chem.*, 2000, Vol. 43, pp. 3093-3102.		
	*	DISCHINO, et al., " Synthesis of Monosodium Salt of Carbon-14 Labeled Paclitaxel (Taxol ®) 2'-Ethyl Carbonate 7-Phophonooxymethyl Ether, a Potential Prodrug of Paclitaxel," *Journal of Labelled Compounds and Radiopharmaceuticals*, Vol. XXXIX, No. 2.		
	*	GREENWALD, et al., "Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates, *J. Org. Chem.*, 1995, Vol. 60, pp. 331-336.		
	*	HALMOS, et al. "Fatty Acid Conjugates of 2'-Deoxy-5'-Fluororidine as Prodrugs for the Selective Delivery of 5-Fluorouracil to Tumor Cells" *Biochemical Pharmacology*, (1992) 44:1:149-155.		
	*	HONG et al., "Nucleoside-ether lipid conjugates as biotransformed prodrugs of antitumor and antiviral nucleosides" *Journal of Lipid Mediators and Cell Signalling*. 10: 159-161 (1994).		
	*	KARMALI, R., "N-3 Fatty Acids: Biochemical Actions In Cancer", *J. Nutr. Sci. Vitaminol. (Tokyo)*, (1992), 148-152. (Abstract)		
	*	MINAMI, M., et al.,"Effects Of Low-Dose Eicosapentaenoic Acid, Docosahexaenoic Acid And Dietary Fat On The Incidence, Growth And Cell Kinetics Of Mammary Carcinomas In Rats", *Oncology*, (1996), 53(5):398-405.		
	*	UEDA et al., "Synthesis and Antitumor Evaluation of 2'-Oxycarbonylpaclitaxels (Paclitaxel02'-Carbonates)", *Bioorganic & Medicinal Chemistry Letters*, Vol. 4, No. 15, pp. 1861-1864, 1994.		
	*	ANSARI et al., "Fatty acid conjugates of xenobiotics," *Toxicol. Lett.* (1995), 75, 1-17.		
	*	Anel, A., et al., "Increased Cytotoxicity Of Polyunsaturated Fatty Acids On Human Tumoral B And And T-Cell Lines Compared With Normal Lymphocytes", *Leukemia*, (1992), 6(7):680-688.		
	*	Anel, B., et al. "Cytotoxicity Of Chlorambucil And Chlorambucil-Fatty Acid Conjugates Against Human Lymphomas And Normal Human Peripheral Blood Lymphocytes", *Biochem Pharmacol*,(1990),40(6):1193-1200.		
	*	Begin, M.E., et al., "Differential Killing Of Human Carcinoma Cells Supplemented With N-3 And N-6 Polyunsaturated Fatty Acids", *J Natl Cancer Inst*, (1986), 77(5):1053-1062. (Abstract)		
	*	Bourat, et al., "Long Chain Esters of Pipotiazine as Long-Acting Psychotropic Pro-Drug", *Med. Chem. Proc. Int. Symp.* 5th (1976) pp. 105-114.		
	*	Braam, J., et al., *Cell*, 60"357-364 (1990)		
	*	Burns, C.P., et al., "Effect Of Docosahexaenoic Acid On Rate Of Differentiation Of Hl-60 Human Leukemia", *Cancer Res*, (1989), 49:3252-3258.		
	*	Carboni et al., "Synthesis of a Photoaffinity Analog of Taxol as an Approach to Identify the Taxol Binding Site on Microtubules", *Journal of Medicinal Chem.* (8 September 1992).		
	*	Chajes, V., et al., "Influence Of N-3 Fatty Acids On The Growth Of Human Breast Cancer Cells In Vitro: Relationship To Peroxides And Vitamin-E", *Breast Cancer Res Treat*, (1995), 34:199-212.		
	*	de Antueno, R.J., et al., "In Vitro Effect Of Eicosapentaenoic And Docosahexaenoic Acids On Prostaglandin E2 Synthesis In A Human Lung Carcinoma", *Biochem Int*, (1989), 19(3):489-496. (Abstract)		
DJ	*	de Smidt, P.C., et al., "Characteristics Of Association Of Oleoyl Derivatives Of 5-Fluorodeoxy-Uridine And Methotrexate With Low-Density Lipoproteins (Ldl)", *Pharm Res*, (1992), 9(4):565-569.		

DJ	*	Deutsch, H.F., et al.,"Cytotoxic Effects Of Daunomycin-Fatty Acid Complexes On Rat Hepatoma", CELLS", *Cancer Res*, (1983), 43:2668-2672.
	*	D'Orlando, et al., "Citicoline (CDP-Choline): Mechanisms of Action and Effects in Ischemic Brain Injury", *Neurol. Res.* (1995) 17: 281-284
	*	Ehringer, W., et al., "A Comparison Of The Effects Of Linolenic (18:3 Omega 3) And Docosahexaenoic (22:6 Omega 3) Acids On Phospholipid Bilayers", *Chem Phys Lipids*, (1990), 54:79-88.
	*	Ertel, et al., "Type III -Agatoxins: A Family of Probes for Similar Binding Sites on L- and N-Type Calcium Channels", *Biochemistry*, 33:5098-5108 (1994)
	*	Falconer, J.S., et al., "Effect Of Eicosapentaenoic Acid And Other Fatty Acids On The Growth *In Vitro* Of Human Pancreatic Cancer Cell Lines", *Br. J. Cancer*, (1994,) 69:826-832.
	*	Ferrari et al., "9-Cis-6,6'-Diapo-Gamma, Gamma-Carotenedioic Acid Derivatives And Pharmaceutical Compositions Containing Them", p. 710. Abs. 20423w, *Chem. Abs.* 95(23), 12/7/81,EP30,009 06/10/81 06/10/81
	*	Georg et al., "The Medicinal Chemistry of Taxol", in "Taxol Science and Applications" ed. Matthew Suffness. Boca Raton: CRC Press, Inc., 1995, pp. 317-375.
	*	Hesse et al., "Inhibitory Effect of Cholesteryl- -Aminobutyrate" Neurolpharmacology, Vol. 24, No. 2, pp. 139-146 (1985)
	*	Higuchi et al., (Editors), Prodrugs as Novel Drug Delivery Systems, Acs Symposium Series, vol. 14, ACS, Washington, 1975, pp. 14-15.
	*	Iwakami, et al., "Inhibition of Arochidonate 5-Lipoxygenase by Phenolic Compounds", Chem. Pharm. Bull. (Japan), 34(9), 3960-3963 (1986)
	*	Jacob, et al., -Aminobutyric Acid Esters.1. Synthesis...", Journal of Medicinal Chemistry, Vol. 28, No. 1, pp 106-110 (1985)
	*	Jacobson, K., et al., Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors, *FEBS Letters* 225:1,2:97-102, (1987).
	*	Jenski, L.J., et al., "Docosahexaenoic Acid-Induced Alteration Of Thy-1 And Cd8 Expression On Murine Splenocytes", *Biochim Biophys Acta*, (1995), 1236(1):39-50.
	*	Jenski, L.J., et al.,"Omega 3 Fatty Acids Increase Spontaneous Release Of Cytosolic Components From Tumor Cells", *Lipids*, (1991), 26(5):353-358.
	*	Jenski, L.J., et al., "Omega-3 Fatty Acid-Containing Liposomes In Cancer Therapy", *Proc Soc Exp Biol Med*, (1995), 210(3):227-233.
	*	Karmali, R.A., et al., "Effect Of Omega-3 Fatty Acids On Growth Of A Rat Mammary Tumor", *J Natl Cancer Inst* (1984), 73(2):457-461. (Abstract)
	*	Karmali, R., "N-3 Fatty Acids: Biochemical Actions In Cancer", *J. Nutr. Sci. Vitaminol. (Tokyo)*, (1992), 148-152. (Abstract)
	*	Kinsella, J.E., et al., "Effects Of Polyunsaturated Fatty Acids On The Efficacy Of Antineoplastic Agents Toward L5178y Lymphoma Cells", *Biochem Pharmacol*, (1993), 45(9):1881-1887. (Abstract)
	*	Kretsinger, R. H., et al., "The EF-Hand, Homologs and Analogs", *Novel Calcium-Binding Proteins*, 17-37 (1991)
	*	Madhavi, N., et al., "Effect Of N-6 And N-3 Fatty Acids On The Survival Of Vincristine Sensitive And Resistant Human Cervical Carcinoma Cells In Vitro", *Cancer Lett*, (1994), 84:31-41.
	*	Makino, et al., Chemical Abstracts, Vol. 106, No. 12, (90177x) issued 23 March 1987, "Pharmaceuticals Permeable to Blood-Brain Barrier".
DJ	*	Marsden, B. J., et al., "H NMR Studies of Synthetic Peptide Analogues of Calcium-Bining Site III of Rabbit Skeletal Troponin C: Effect of the Lanthanum Affinity of the Interchange of Aspartic Acid and Asparagine Residues at the Metal Ion Coordinating Positions", *Biochemistry*, 27:4198-4206 (1988)

DJ	*	Mazumdar, et al., "Preparation and Evaluation of Ethambutol Derivatives", Indian J. Pharm. Sci. 47(6): 179-180 (1985)
	*	Minami, M., et al.,"Effects Of Low-Dose Eicosapentaenoic Acid, Docosahexaenoic Acid And Dietary Fat On The Incidence, Growth And Cell Kinetics Of Mammary Carcinomas In Rats", *Oncology*, (1996), 53(5):398-405.
	*	Nicolaou et al., "Design, Synthesis and Biological Activity of Protaxols", *Nature*, 364: 464-466 (July).
	*	Nishio, et al., "Novel Water-soluble Derivatives of Docosahexaenoic Acid Increase Diacyl-Glycerol Production Mediated by Phosphatidylcholine-Specific Phospholipase C", *Proc. Soc. Exp. Biol. Med.* (1993) 203(2):200-208.
	*	Oshima, M., et al., "Effects Of Docosahexaenoic Acid (Dha) On Intestinal Polyp Development In Apc Delta 716 Apc Delta 716 Knockout Mice", *Carcinogenesis*, (1995), 16(11):2605-2607.
	*	Pascale, A.W., et al., "Omega-3 fatty acid modification of membrane structure and function. Alteration by docosahexaenoic acid of tumor cell sensitivity to immune cytolysis", *Nutr Cancer*, (1993), 19(2):147-157.
	*	Plumb, J.A., et al., "Effect Of Polyunsaturated Fatty Acids On The Drug Sensitivity Of Human Tumour Cell Lines Resistant To Either Cisplatin Or Doxorubicin", *Br J Cancer*, (1993), 67:728-733.
	*	POUILLART, "Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies," *Life Sci.* (1998), 63(20), 1739-1760.
	*	Rocco et al., "Models of Fibronectin", The EMBO Journal, 6: 2343-2349 (1987).
	*	Rose, W.C., Preclinical Antitumor Activity of Taxanes", in "Taxol Science and Applications" ed. Matthew Suffness. Boca Raton: CRC Press, Inc., 1995, pp. 317-375.
	*	Schabitz, et al., "The effects of Prolonged Treatment with Citicoline in Temporary Experimental Focal Ischemia", *J. Neurol. Sci.*, (1996) 138(1-2):21-25 (Abstract)
	*	Shashoua, et al., -Aminobutyric Acid Esters.1. Synthesis...", *J. of Med. Chem.*, Vol. 27, pp. 659-664 (1984)
	*	Shea, et al., *Developmental Brain Research*, 21:307-314 (1985).
	*	Specter, R., "Fatty Acid Transport Through the Blood-Brain Barrier.", *J. of Neurochem.*, 50:2:639-643 (1988)
	*	Suphioglu, C., et al., "Molecular Cloning and Immunological Characterization of Cyn d 7, A Novel Calcium-Binding Allergin from Bermuda Grass Pollen", *FEBS Letters*, 402:167-172 (1997)
	*	Swindell, et al., "Characterization of the Taxol Structure-Activity Profile for the Locus of the A-Ring Side Chain Side Chain", *Bioorganic & Medicinal Chem. Ltrs.*, Vol.4, No. 12, pp. 1531-1536. (1994)
	*	Tessier, C., et al., "Docosahexaenoic Acid Is A Potent Inhibitor Of Rat Uterine Stromal Cell Proliferation", *Biochem Biophys Res Commun*, (1995), 207(3):1015-1021.
	*	Tinsley, I.J., et al., "Influence Of Dietary Fatty Acids On The Incidence Of Mammary Tumors In The C3h Mouse", Ch3h Mouse", *Cancer Res*, (1981), 41:1460-1465.
	*	Young, et al., *FEBS Letters*, 338:212-216 (1994)
	*	Zerouga, M., et al., "Phospholipid Class As A Determinant In Docosahexaenoic Acid's Effect On Tumor Cell Viability", *Anticancer Res*, (1996), 16:2863-2868. (Abstract)
	*	Zijlstra, J.G., et al., "Influence Of Docosahexaenoic Acid In Vitro On Intracellular Adriamycin Concentration In Lymphocytes And Human Adriamycin-Sensitive And Resistant Small-Cell Lung Cancer Cell Lines, And On Cytotoxicity In The Tumor Cell Lines", *Int J Cancer*, (1987), 40:850-856.
DJ	*	International Search Report, PCT/US 00/06160, International Filing Date: 09/03/2000

EXAMINER	DATE CONSIDERED
/Donna Jagoe/	(05/31/2006)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/846,838 , filed May 1, 2001 , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	7

APPLICATION NO.: 10/618,884	ATTY. DOCKET NO.: N0260.70058US00
FILING DATE: July 14, 2003	CONFIRMATION NO.: 5880
APPLICANT: Victor E. Shashoua et al.	
GROUP ART UNIT: 1614	EXAMINER: Donna A. Jagoe

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
DJ	*	3,539,573		Schmutz	11/10/1970
	*	3,621,048		Bauman	11/16/1971
	*	4,097,597		Horrom, et al.	06/27/1978
	*	4,218,234	A	Nadasy, et al.	08/19/1980
	*	4,346,085		Growdon, et al.	08/24/1982
	*	4,351,831		Growden, et al.	09/28/1982
	*	4,550,109		Folkers, et al.	10/29/1985
	*	4,554,272		Bock, et al.	11/19/1985
	*	4,558,049		Bernardi, et al.	12/10/1985
	*	4,684,646		Chang, et al.	08/04/1987
	*	4,868,161		E. Roberts	09/19/1989
	*	4,902,505		Pardridge, et al.	02/20/1990
	*	4,933,324		Shashoua	06/12/1990
	*	4,939,174		Shashoua	07/03/1990
	*	5,169,762		Grey, et al.	12/08/1992
	*	5,284,876		Shashoua	02/08/1994
	*	5,532,372		Saji, et al.	07/02/1996
	*	5,532,374		Lee, et al.	07/02/1996
	*	5,545,719		Shashoua	08/13/1996
	*	5,603,959	A1	Horrobin, et al.	02/18/1997
	*	5,604,198		Poduslo, et al.	02/18/1997
	*	5,646,180		Chaturvedi	07/18/1997
	*	5,824,701	A	Greenwald et al.	10/20/1998
	*	5,827,819		Yatvin, et al.	10/27/1998
	*	5,955,459		Bradley, et al.	09/21/1999
	*	6,005,004		Katz et al.	12/21/1999
	*	6,024,977		Yatvin et al.	02/15/2000
	*	6,107,499		Shashoua	08/22/2000
	*	6,245,811	B1	Horrobin et al.	06/12/2001
	*	6,407,075	B1	Scott et al.	06/18/2002
	*	6,407,137	B2	Shashoua	06/18/2002
	*	6,448,392	B1	Hostetler et al.	09/10/2002
	*	6,576,636	B2	Webb et al.	06/10/2003
	*	6,602,902	B2	Shashoua et al.	08/05/2003
DJ	*	6,627,601	B2	Shashoua	09/30/2003

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/618,884	ATTY. DOCKET NO.: N0260.70058US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 14, 2003	CONFIRMATION NO.: 5880
	APPLICANT: Victor E. Shashoua et al.	
Sheet 2 of 7	GROUP ART UNIT: 1614	EXAMINER: Donna A. Jagoe

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
DJ	*	AU	770519		Protarga, Inc.	04/05/2001	
	*	AU	746472		Protarga, Inc.	06/15/1999	
	*	DE	24 56 947	A1	Pfizer, Inc.	06/12/1975	With English Abstract
	*	DE	29 32 869	A1	Ciba-Geigy AG	02/28/1980	
	*	EP	0909183	B1	Protarga, Inc.	04/21/1999	
	*	EP	0 599 576	A1	Scotia Holding, PLC	06/01/1994	
	*	EP	0 311 100	A2	F. Hoffman	04/12/1989	
	*	EP	0 091 694	A1	Eisai Co., Ltd.	10/19/1983	
	*	EP	0909183	B1	Protarga, Inc.	08/11/2004	
	*	EP	0 035 375	A1	Takeda Yakuhin Kogyo Kabushiki Kaisha	09/09/1981	
	*	EP	0 761 644	A	Kao Corporation	03/12/1997	
	*	FR	2 592 883	A	Ire Celltarg SA	07/17/1987	
	*	JP	75-9469		New OJI Paper Co., Ltd	07/29/1976	Abstract
	*	JP	8245378	A	Sagami Chem Res Centerfuji Yakuhin:KK	09/24/1996	Abstract
	*	JP	7082146		Sagami Chem Res Center	03/28/1995	Abstract
	*	JP	6072868		Maruha Corp.	03/15/1994	Abstract
	*	JP	61204136		Teijin Ltd.	09/10/1986	Abstract
	*	JP	10168047	A	Kao Corp	06/23/1998	Abstract
	*	JP	2256624	A	Sagami Chem Res Centre	10/17/1990	Abstract
	*	JP	55053208	A	Mitsubishi Chem Ind. Ltd.	04/18/1980	Abstract
	*	SU	477159	A	Phytopathology Inst.	10/14/1976	Abstract
	*	WO	02/087586	A1	Control Delivery Systems, Inc.	11/07/2002	
	*	WO	01/62085	A1	Medinox, Inc.	08/30/2001	
	*	WO	00/01417		Cyclacel Limited	01/13/2000	
	*	WO	00/53231		Protarga, Inc.	09/14/2002	
	*	WO	00/67802		Protarga, Inc.	11/16/2002	
	*	WO	98/09621		Scotia Holdings, PLC	04/12/1998	
	*	WO	99/26620		Neuromedia, Inc.	06/03/1999	
	*	WO	99/44600		Scotia Holding, PLC	09/10/1999	
	*	WO	89/07938		Shashoua	09/08/1989	
	*	WO	98/17325		Oregon Health Sciences University	04/30/1998	
	*	WO	97/33173	A	The Regents of the University f California	09/12/1997	
	*	WO	96/34855		Scotia Holding PLC	11/7/1996	
DJ	*	WO	96/22303		Commonwealth of Scientific and Industrial Research	07/25/1996	

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/618,884	ATTY. DOCKET NO.: N0260.70058US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 14, 2003	CONFIRMATION NO.: 5880
	APPLICANT: Victor E. Shashoua et al.	
	GROUP ART UNIT: 1614	EXAMINER: Donna A. Jagoe
Sheet 3 of 7		

FOREIGN PATENT DOCUMENTS

DJ	*	WO	96/04001		Molecular/Structural Biotechnologies, Inc.	02/15/1996	
	*	WO	85/00520		The McLean Hospital Corp.	04/06/1989	
	*	WO	02/087586	A1	Control Delivery Systems, Inc.	11/07/2002	
	*	WO	92/06089	A	H. Lundbeck	04/16/1992	
	*	WO	98/32718	A	Norsk Hydro	07/30/1998	
	*	WO	98/43994	A	Genzyme Corporation	10/08/1998	
DJ	*	WO	93/1168		Schering Aktiengesellschaft Berling Underbergkamen	06/24/1993	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
DJ	*	AIHARA, M. et al., "Effects of liposteroid on skin lesions in autoimmune MRLlpr/lpr mice," Journal of Dermatological Science, 16, 1997, pp. 45-51.		
	*	FUNAUCHI, M. et al., "Effects of liposteroid on the hemophagocytic syndrome in systemic lupus erythematosus," Lupus, 12, 2003, pp. 483-485.		
	*	HAZARD Database, "Chemical Tertogens, Carcinogens, Mutagens: Dexamethasone palmitate,"http://www.evol.nw.ru/labs/lab38/spirov/hazard/dexamethasone_palmitate.html, printed from website on August 31, 2004.		
	*	HOSHI, K. et al., "Double-Blind Study with Liposteroid in Rheumatoid Arthritis," Drugs Exptl. Clin. Res., XI(9), 1985, pp. 621-626.		
	*	KARMALI, R.A., et al., "Effect of Omega-3 Fatty Acids on Growth of a Rat Mammary Tumor," *J Natl Cancer Inst*, 73(2), 1984, pp. 457-461. (Abstract)		
	*	MIZUSHIMA, Y. et al., "Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion,"		
	*	UEDA et al., "Synthesis and Antitumor Evaluation of 2'-Oxycarbonylpaclitaxels (Paclitaxel-2'-Carbonates)," Bioorganic & Medicinal Chemistry Letters, Vol. 4, No. 15, 1994, pp. 1861-1864.		
	*	YAMATSU et al., "Polyprenyl Carboxylic Acid Amides," Chemical Abstracts, Vol. 100, No. 19 issued 7 May 1984, p. 555, Abstract No. 156839z, EP91, 694, dated 19 October 1983.		
	*	YOKOYAMA, K. et al., "Development of a Corticosteroid Incorporated in Lipid Microspheres (Liposteroid)," Drugs Exptl. Clin. Res., XI(9), 1985, pp. 611-620.		
DJ	*	"Cytosar-U cytarabine for injection, USP," Product insert, 2/2002.		
	*	"Dexamethasone palmitate: Chemical Teratogens, Carcinogens, Mutagens," CAS# [33755-46-3],		no
		ACX# [11012259], http://www.evol.nw.ru/labs/lab38/spirov/hazard/dexamethasone_palmitate.html		dat
DJ	*	AIHARA, M., et al., "Effects of liposteroid on skin lesions in autoimmune MRL*lpr/lpr* mice," *J. of Dermatological Science* 16 (1997), pp. 45-51.		
	*	ALTHAUS, I.W. et al., "The amphiphilic properties of novenamines determine their activity as inhibitors of HIV-1 RNase H," Experientia, Vol. 52, 1996, pp. 329-335, XP008039697.		
	*	ATTARD, George S., et al., "Phase behaviour of novel phospholipid analogues." Chemistry and Physics of Lipids, vol. 76, 1995, pages 41-48 .		
	*	BALDESSARINI, et al., "Dopamine and Pathophysiology of Dyskinesis...", Ann. Rev. Neurosci. 3:23-41 (1980).		
DJ	*	BOLWELL, et al., "High dose cytarabine: a review," *Leukemia* 5 (5/1988), pp. 253-60 Abstract.		

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/618,884	ATTY. DOCKET NO.: N0260.70058US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 14, 2003	CONFIRMATION NO.: 5880
	APPLICANT: Victor E. Shashoua et al.	
Sheet 4 of 7	GROUP ART UNIT: 1614	EXAMINER: Donna A. Jagoe

OTHER ART — NON PATENT LITERATURE DOCUMENTS

DJ	*	BRIDGES, A.J. et al., "N^6-(2,2-Diphenylethyl)adenosine, a Novel Adenosine Receptor Agonist with Antipsychotic-like Activity", J. Med. Chem. 30:1709-1711 (1987)		
	*	BRUTOVSKA, A. et al., "Isothiocyanates and Their Synthetic Producers. VIII. The Synthesis and the Study of Spectral Features of Substituted Monothiourethanes," *Chem. Zvesti*, vol. 23, 1969, pp. 736-741.		
	*	DATABASE BEILSTEIN, *Beilstein Institute for Organic Chemistry*, Frankfurt-Main, DE, 29 June 1989, XP002311506, Database accession no. 2146750 (BRN).		
	*	DATABASE BEILSTEIN, *Beilstein Institute for Organic Chemistry*, Frankfurt-Main, DE, 15 February 1990, XP002311507, Database accession no. 3166362 (BRN).		
	*	DATABASE BEILSTEIN, *Beilstein Institute for Organic Chemistry*, Frankfurt-Main, DE, 29June 1989, XP002311508, Database accession no. 2270240 (BRN).		
	*	DATABASE BEILSTEIN: 29 June 1989 (1989-06-29), XP002329550; Database accession no. 2199386 (BRN), Abstract & SU 477 159 A (STREL'TSOV, BLIZNYUK) 1976		
	*	DATABASE HCAPLUS ACS, 6 September 1991, XP002311505, retrieved from STN, Database accession no. 115:91935/DN, RN 2411-58-7, 135346-35-9, 7418-03-3.		
	*	DATABASE HCAPLUS ACS: 11 October 2000 (2000-10-11); XP002329554; Retrieve from STN Database accession no. 134:193273/DN, Abstract, RN327082-01-9; & CHEN, ZAI-XIN ET AL: ZHONGGUO YIYAO GONGYE ZAZHI BIANJIBU, vol 31, no. 6, 2000, pages 265-268		
	*	DATABASE HCAPLUS ACS: 12 May 1984 (1984-05-12); XP002329551; Retrieved from STN Database accession no. 93:90207/DN; Abstract, RN52067-53-5, 74551-09-0 & JP 55 053208 A (Mitsubishi Chemical Ind. Co.); 18 April 1980 (1980-04-18)		
	*	DATABASE HCAPLUS ACS: 2 July 1998 (1998-07-02); XP002329553; Retrieved from STN Database accession no. 129:135899/DN, Abstract, RN210540-30-0, -31-1 & JP 10 168047 A (KAO Corp.), 23 June 1998 (1998-06-23)		
DJ	*	DATABASE HCAPLUS ACS; 28 June 1991 (1991-06-28); XP002329552; Retrieved from STN Database accession no. 114:254032, Abstract, RN29271-27-0, 49802-20-2, 134036-50-3 & JP 02 256624 A (Sagami Chemical Research Center) 17 October 1990 (1990-10-17)		
	*	~~DeVITA, JR., et al., *Cancer Principles & Practice of Oncology*, 5th Ed., pp. 443-444.~~		no date
DJ	*	DHOPESHWARKER, G., "Fatty Acid Transport Through the Blood-Brain Barrier.", *Biochim Biophys. Acta* 255:572-579.		
	*	Domagala, John M., et al., "New Class of Anti-HIV-1 Agents Targeted Toward the Nucleocapsid Protein NCp7: The 2,2ÿ-Dithiobisbenzamides." Bioorganic & Medicinal Chemistry, Vol. 5, No. 3, pages 569-579 (1997).		
	*	FUNAUCHI, M., et al., "Effects of liposteroid on the hemophagocytic syndrome in systemic lupus erythematosus," *Lupus* 12 (2003), pp. 483-485.		
	*	GARZON-ABURBEH, et al., "A Lymphotropic Product of L-Dopa:Synthesis" J. Med. Chem. 29: 687-691 (1986)		
	*	GUÉNARD, et al., "Effects of the Hydrophobicity of Taxoids on their Interaction with Tubulin", *Bioorganic & Medicinal Chemistry* Vol. 8, (2000) pp. 145-156.		
	*	GUFFY, M.M., et al., "Effect Of Cellular Fatty Acid Alteration On Adriamycin Sensitivity In Cultured L1210 Murine Leukemia Cells", *Cancer Res*, (1984), 44:1863-1866.		
	*	GUILLONNEAU, C. et al., "Synthesis of 9- *O*-Substituted Derivatives of 9-Hydroxy-5,6-dimethyl-6*H*-pyrido[4,3-*b*]carbazole-1-carboxylic Acid (2-(Dimethylamino)ethyl)amide and Their 10- and 11-Methyl Analogues with Improved Antitumor Activity," *J. Med. Chem.* 1999, 42, pp. 2191-2203, XP-002311501.		
	*	GUNNE, et al., "Oral Dyskinesia in Rats Following Brain Lesions and Neuroleptic Drug Administration", Psychopharmacology 77:134-139 (1982)		
	*	HAAS, et al., "Effektivität intramuskulär verabreichten Cytosin-Arabinosids bei der ambulanten Behandlung von Kindern mit akuter Leukämie in Remission," *Onkology* (2/1980) pp. 53-57. (English summary included).		
	*	HESSE, et al., "Uptake in brain neurophysiological activity of two lipid esters of gamma-amin butyric acid" *Neuropharmacol.* 27:6:637-40 (1988).		
DJ	*	HO, et al., "Pharmac logic Studies of Cyclocytidine and Arabinosylcytosine in Dogs," *Drug Metabolism and Disposition* 3(4) (1975), pp. 309-313.		

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/618,884	ATTY. DOCKET NO.: N0260.70058US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 14, 2003	CONFIRMATION NO.: 5880
	APPLICANT: Victor E. Shashoua et al.	
Sheet 5 of 7	GROUP ART UNIT: 1614	EXAMINER: Donna A. Jagoe

OTHER ART — NON PATENT LITERATURE DOCUMENTS

DJ	*	HO, et al., "Pharmacology of 5'-Esters of 1-β-D-Arabinofuranosylcytosine," *Cancer Research* 37 (6/1977), pp. 1640-1643.		
	*	HONG, C.I. et al., "Synthesis and Biological Activity of N^6-(*n*-Alkylureido)purine Ribonucleosides and Their 5ÿ-Phosphates," *J. Pharm. Sci.*, Vol. 67, No. 4, April 1978, pp. 569-571, XP008039688.		
	*	HOSHI, K., et al., "Double-blind study with liposteroid in rheumatoid arthritis," *Drugs Exptl. Clin. Res.* XI(9) (1985), pp. 621-626.		
	*	International Search Report in PCT/US02/09389, mailed February 10, 2004		
	*	JACOB, et al., "Alpha-Aminobutyric Acid Esters.3. Synthesis, brain uptake and pharmacological properties of C-18 Glyceryl lipid esters of BAGA with varying degree of unsaturation," *J. Med. Chem.* 30:1573-6 (1987).		
	*	JACOB, et al., "Synthesis, brain uptake and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor, gamma-vinyl-GABA," *J. Med. Chem.* 33:733-6 (1990).		
	*	Janusz, John J., et al., "Vanilloids. 1. Analogs of Capsaicin with Antinociceptive and Antiinflammatory Activity." J. Med. Chem., Vol. 36, No. 18, pages 2595-2604 (1992).		
	*	Kageyama, Yuichi, et al., "Novel approaches to prodrugs of anticancer diaminodichloroplatinum(II) complexes activated by stereoselective enzymatic ester hydrolysis." Journal of Inorganic Biochemistry, Vol. 70, pp. 25-32 (1998).		
	*	Kalgutkar, Amit S., et al., "Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors." Journal of Medicinal Chemistry, pages 2860-2870 (2000)		
	*	Kariko, Katalin, et al, "n-DECYL-NHpppA2ÿ p5ÿ A2ÿ p5ÿ A A Phosphatase-Resistant, Active pppA2ÿp5ÿ A2ÿ p5ÿ A Analog." Biochemical and Biophysical Research Communications, Vol. 128, No. 2, pp. 695-698 (1985).		
	*	KATAOKA, et al., "Effect and Mode of Action of N^4-Behenoyl-β-D-Arabinofuranosylcytosine," *Recent Results in Cancer Research* 70 (1980), pp. 147-151.		
	*	KONIGSTORFER et al., "Biosynthesis of Ependymins from Goldfish Brain", J. Biol. Chem., vol. 264 (23): 13689-13692 (1989).		
	*	KONIGSTORFER et al., "Molecular Characterization Of An Ependymin Precursor from Goldfish Brain", J. Neurochem., 52:310-312 (1989).		
	*	KRISTIAN et al., "Isothiocyanates and Their Synthetic Producers. X. Synthesis of 3-Substituted 2-Thioxo-4-Oxo-3,4-Dihydro-2H-1,3-Benzoxazines," *Collect. Czech. Chem. Commun.*, vol. 37, 1972, pp. 2972-2974.		
	*	LEE, HEEJOO et al., "Syntheses of 5-Fluorouracil-Fat Conjugates and Evaluation of Their *in vitro* Cytotoxic Activity," *Yakhak Hoechi*, vol. 34, 1990, pp. 395-400.	Abstract only	N
	*	LENNARTZ, *Chem. Ber.*, vol. 75, 1942, pp. 833-842.		N
	*	LEONARD, et al., "Identification and Characterization of mRNAs Regulated by Nerve Growth Factor in PC12 Cells", *Molecular and Cellular Biology*, 7(9):3156-67 (1987)		
	*	LIU, J. et al., "New Approaches for the Preparation of Hydrophobic Heparin Derivatives," *J. of Pharmaceutical Sciences*, Vol. 83, No. 7, July, 1994, pp. 1034-1039, XP008038024.		
	*	LOHR, et al., "Neuroleptic-Induced Movement Disorders...", Psychiatry, Vol. 3, 1-16 (1989).		
	*	MARDER, S.R., *J. Clin. Psychiatry* (supp 3), *Management of Schizophrenia* 57:9-13 (1996)		
	*	McGuigan, C. et al., "Phosphoramidates as potent prodrugs of anti-HIV nucleotides: studies in the amino region." Antiviral Chemistry & Chemotherapy, V ol. 7, No 1, pp. 31-36 (1996).		
	*	McGuigan, C., et al., "Synthesis and Evaluation of s me masked phosphate esters of the anti-herpesvirus drug 882C (netivudine) as potential antiviral agents." Antiviral Chemistry & Chemotherapy, Vol. 9, pp. 233-243 (1998).		
DJ	*	MEIER et al., "Molecular Cloning of Bovine and Chick Nerve Growth (NGF) . . . ", *The EMBO Journal*, vol. 5, 7:1489-1493 (1986).		

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/618,884	ATTY. DOCKET NO.: N0260.70058US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 14, 2003	CONFIRMATION NO.: 5880
	APPLICANT: Victor E. Shashoua et al.	
Sheet 6 of 7	GROUP ART UNIT: 1614	EXAMINER: Donna A. Jagoe

OTHER ART – NON PATENT LITERATURE DOCUMENTS

DJ	*	MEYER, K. L. et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents," *J. Med. Chem.* 1991, 34, pp. 1377-1383, XP-002311504.		
	*	Miroshnikova, Olga V., et al., "Structure-Activity Relationship in the Series of Eremomycin Carboxamides." The Journal of Antibioti cs, Vol. 53, No. 3, pp. 286-293 (2000).		
	*	MIZUSHIMA, Y., et al., "Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion," *Annals of the Rheumatic Diseases*, 41 (1982), pp. 263-267.		
	*	Nicolaou, Anna, et al., "Synthesis and Properties of Novel Lipopeptides and Lipid Mimetics." Journal of Peptide Science, Vol. 3, pp. 291-298 (1997).		
	*	PCT/GB97/02362 – Scotia Holdings, PLC - Search Report - February 20, 1998		
	*	PCT/GB99/00563 - Scotia Holdings, PLC - Search Report - August 19, 1999		
	*	PCT/US00/06160 - Protarga, Inc. - Search Report – October 4, 2001		
	*	PCT/US00/12752 - Protarga, Inc. - Search Report - October 31, 2000		
	*	PCT/US89/00757 – Shashoua - Search Report - June 14, 1989		
	*	PCT/US91/03346 – Shashoua - Search Report - September 6, 1991		
	*	PCT/US97/08792 - Neuromedica, Inc. - Search Report - October 28, 1997		
	*	PCT/US97/08866 - Neuromedica, Inc. - Search Report - September 3, 1997		
	*	PCT/US97/08867 - Neuromedica, Inc. - Search Report - January 9, 1998		
	*	PCT/US98/24412 - Neuromedica, Inc. - Search Report - February 22, 1999		
	*	PCT/US98/24421 - Neuromedica, Inc. - Search Report - March 3, 1999		
	*	PCT/US98/24490 - Neuromedica, Inc. - Search Report - February 26, 1999		
	*	PCT/US99/01786 - Neuromedica, Inc. - Search Report - July 6, 1999		
	*	PONPIPOM, M.M. et al., "Structure-Activity Relationships of C1 and C6 Side Chains of Zaragozic Acid A Derivatives," *J. Med. Chem.* 1994, 37, pp. 4031-4051, XP-002311499.		
	*	PUGLISI, G. et al., "Synthesis of Methotrexate ɣ,ɣ-Bis(Amides) and Correlation of Thermotropic and DPPC Biomembrane Interaction Parameters with Their Anticancer Activity," *Drug Development Research* 44, pp. 62-69 (1998), XP008039189.		
	*	Rasmusson, Gary H., "Azasteroids: Structure-Activity Relationships for Inhibition of 5ɣ-Reductase and Androgen Receptor Binding." J. Med. Chem., Vol. 29, pp. 2298-2315 (1986).		
	*	RENTSCH, et al., "Pharmacokinetics of N^4-Octadecyl-1-β-D-Arabinofuranosylcytosine in Plasma and Whole Blood after Intravenous and Oral Administration to Mice," *J. Pharm. Pharmacol.*49 (1997), pp. 1076-1081.		
	*	ROARK, W. H. et al., "Inhibitors of Acyl-CoA:Cholesterol Acyltransferase (ACAT). 2. Modification of Fatty Acid Anilide ACAT Inhibitors: Bioisosteric Replacement of the Amide Bond," *J. Med. Chem.* 1993, 36, pp. 1662-1668, XP002924002.		
	*	SASSE, A. et al., "Development of Chiral *N*-Alkylcarbamates as New Leads for Potent and Selective H_3-Receptor Antagonists: Synthesis, Capillary Electrophoresis, and in Vitro and Oral in Vivo Activity," *J. Med. Chem.* 1999, 42, pp. 593-600, XP-002311502.		
	*	SCOTT, et al., "Isolation and nucleotide sequence of cDNA encoding...", *Nature* 302, 538-540 (1983).		
	*	SEKI, J., et al., "A nanometer lipid emulsion, lipid nano-sphere (LNS®), as a parenteral drug carrier for passive drug targeting," *International Journal of Pharmaceutics* 273 (2004), pp. 75-83.		
	*	SERGHERAERT, C. et al., "Synthesis and Anti-HIV Evaluation of D4T and D4T 5'-Monophosphate Prodrugs," *J. Med. Chem.* 1993, 36, pp. 826-830, XP-002311498.		
	*	SHASHOUA, et al., "Evidence for the In Vivo Polymerization of Ependymin: Brain Extracellular Glycoprotein", *Brain Research*, 522, 181-190 (1990)		
DJ	*	SHASHOUA, V.E., "Ependymin, a Brain Extracellular Glycoprotein, and CNS Plasticity," reprinted from *Activity-Driven CNS Changes in Learning and Development*, vol. 627 of the Annals of the New York Academy of Sciences, Aug. 5, 1991).		

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/618,884	ATTY. DOCKET NO.: N0260.70058US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 14, 2003	CONFIRMATION NO.: 5880
	APPLICANT: Victor E. Shashoua et al.	
Sheet 7 of 7	GROUP ART UNIT: 1614	EXAMINER: Donna A. Jagoe

OTHER ART — NON PATENT LITERATURE DOCUMENTS

DJ	*	Shashoua, V.E., "The Role of Brain Extracellular Proteins...", *Cellular and Mol. Neurobiol.*, 5 (1/2):183-207 (1985).		
	*	SHASHOUA, V.E., "The role of ependymin in the development of long lasting synaptic charges" *J. Physiol.* Paris, 83:232-239 (1988-1989)		
	*	SIMONI, D. et al., "Geiparvarin Analogues. 2. Synthesis and Cytostatic Activity of 5-(4-Arylbutadienyl)-3(2*H*)-furanones and of *N*-Substituted 3-(4-Oxo-2-furanyl)-2-buten-2-yl Carbamates," *J. Med. Chem.* 1991, 34, pp. 3172-3176, XP-002311503.		
	*	Smrt[a], J., et al., "Synthesis of Some Nucleolipids." Collection Czechoslov. Chem. Commun., Vol. 45, pp. 927-931 (1980).		
	*	Supplementary partial European search report from related European Patent Application EP 02731170.3, dated June 22, 2005		
	*	Supplementary Partial European Search Report in Application No. PCT/US02/09389, mailed January 5, 2005.		
	*	TANAKA, T. et al., "Synthesis and Antioxidant Activity of Novel Amphipathic Derivatives of Tea Polyphenol," *Bioorganic & Medicinal Chemistry Letters* 8 (1998), pp. 1801-1806.		
	*	TERASAWA, et al., "Neurocalcin" a novel calcium binding protein from bovine brain" *J. Biol. Chem.*, 267:27 (1992), pages 19596-19599		
	*	TSUSHIMA, S. et al., "Syntheses and Biological Activities of *N*-Alkyl- and *N*-Alkenylcarbamoyl Phospholipids," *Chem. Pharm. Bull.* 32(7): pp. 2700-2713 (1984), XP-002311500.		
	*	Turesky, Samuel, et al., "*In Vitro* Chemical Inhibition of Plaque Formation." J. Periodontol., Vol. 43, pp. 263-269 (1972).		
	*	WASHBURNE, S. S. et al., "Isocyanates Derived from Fatty Acids by the Trimethylsilyl Azide Modification of the Curtius Rearrangement," *Journal of the American Oil Chemists' Society*, American Oil Chemists' Society, Champaign, U.S., vol. 49, 1972, pp. 694-695, XP008039249.		
	*	YAMAMOTO et al., "The Survival of Rat Cerebral Cortical Neurons in the Presence of Trophic APP Peptides" *J. Neurobiol.* 25, 585-594 (1994).		
	*	YOKOKAWA, et al., "The Synthesis of Rat Cerebral Cortical Neurons in the Presence of EF - Hand Type Calcium-Binding Peptides" *Chem. Lett*, 1627-1630 (1989).		
	*	YOKOYAMA, K., et al., "Development of a corticosteroid incorporated in lipid microspheres (liposteroid)," *Drugs Exptl. Clin. Res.* XI(9) (1985), pp. 611-620.		
	*	YOSHIDA, et al., "N^4-Behenoyl-1-β-D-Arabinofuranosylcytosine(BH-AC) Pharmacokinetics" *Cancer and Chemical Treatment* (*Cancer and Chemotherapy*) 14(6) (1987), Part I pp. 1820-1824 – Japanese Language		
	*	YOSHIDA, et al., "Pharmacokinetics of High Dose Treatments of N^4-Behenoyl-1-β-D-Arabinofuranosylcytosine (BH-AC)" *Cancer and Chemical Treatment* (*Cancer and Chemotherapy*) 14(6) (1987), Part I pp. 1820-1824 – English Translation		
DJ	*	YOSHIDA, et al., *Cancer and Chemotherapy* 14(6) (1987), Part I pp. 1820-1824 – English Abstract		

EXAMINER:	DATE CONSIDERED:
/Donna Jagoe/	(05/31/2006)

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

•a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/107,537, filed March 25, 2002, and/or Serial No. 10/108255, filed March 25, 2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]